USANA Health Sciences Inc. - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for USANA Health Sciences, Inc., covering the period ended October 2, 2004. USANA develops, manufactures, and distributes nutritional and personal care products primarily through a network marketing system of independent "Associates" and direct sales to "Preferred Customers." The company operates two reportable segments: Direct Selling (principal business) and Contract Manufacturing.
Key Financial Metrics
| Metric | Quarter Ended Oct 2, 2004 | Quarter Ended Sep 27, 2003 | 9 Months Ended Oct 2, 2004 | 9 Months Ended Sep 27, 2003 |
|---|---|---|---|---|
| Net Sales | $68.7 million | $52.5 million | $197.7 million | $140.5 million |
| Gross Profit | $51.9 million (75.6% margin) | $41.1 million (78.4% margin) | $149.7 million (75.7% margin) | $109.5 million (77.9% margin) |
| Net Earnings | $8.0 million | $6.1 million | $21.6 million | $14.0 million |
| Diluted EPS | $0.39 | $0.28 | $1.05 | $0.66 |
| Cash & Equivalents | $21.4 million | $10.3 million (end of prior period) | $21.4 million | $10.3 million |
| Operating Cash Flow (9mo) | $31.4 million (vs $25.7 million prior year) | |||
| Debt | No long-term debt outstanding; $10M line of credit available (unused). |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 30.8% for the quarter and 40.7% for the nine months. Growth was driven by a 13.8% increase in the active Associate base, new market openings in Singapore and Mexico, and favorable foreign currency translation.
- Margin Compression: Gross profit margins declined slightly (75.6% vs 78.4% for the quarter). This was attributed to inventory valuation allowances for obsolete Sensé products prior to a relaunch and higher raw material costs for Coenzyme Q10 (CoQ10).
- Foreign Currency Impact: The company reported a net foreign currency loss of $576,000 for the quarter (vs a gain of $385,000 in the prior year) due to a significant weakening of the U.S. dollar in late Q3 2004.
- Share Repurchases: The company expended $21.7 million to retire 760,000 shares during the nine-month period, reducing outstanding shares.
Guidance, Outlook, and Risks
- Guidance: Management expects consolidated net sales of approximately $72 million for Q4 2004 and approaching $270 million for the full fiscal year 2004. Diluted EPS for the fiscal year is expected to approximate $1.46.
- Operational Challenges: West Coast shipping port congestion is causing delays and potential airfreight cost increases for shipments to Australia. The company anticipates this to persist until February 2005.
- Product Updates: The Sensé product line was relaunched with new patent-pending self-preserving technology to eliminate parabens.
- Risks: Key risks include reliance on the network marketing model, high Associate turnover, regulatory scrutiny of network marketing, foreign currency fluctuations, and supply chain constraints for key ingredients like CoQ10.
Investor Verification Checklist
- Verify the sustainability of the 30%+ revenue growth rate given the one-time impact of new market openings (Singapore, Mexico).
- Monitor the resolution of West Coast port congestion and its impact on Q4 logistics costs and inventory levels.
- Track the gross margin recovery in the Contract Manufacturing segment, which dropped to 10.5% due to facility upgrades and inventory obsolescence.
- Assess the impact of the $21.7 million share repurchase on future capital availability for expansion.
- Review the effectiveness of the new Sensé product formulation in reversing inventory obsolescence trends.